Commentary

Video

Dr Svoboda on the Investigation of huCART19-IL18 in Relapsed/Refractory Lymphoma

Jakub Svoboda, MD, discusses the investigation of huCART19-IL18 in patients with relapsed/refractory lymphomas that have progressed.

Jakub Svoboda, MD, associate professor, medicine, Hematology-Oncology, attending, the Hospital of the University of Pennsylvania; co-chair, Lymphoma Tumor Board and Case Conference; member, Data Safety Monitoring Committee, Abramson Cancer Center, discusses the ongoing investigation of armored huCART19-IL18 in patients with relapsed/refractory lymphomas following progression on treatment with an anti-CD19 CAR T-cell therapy.

At the 2024 ASCO Annual Meeting, Svoboda and colleagues shared that treatment with huCART19-IL18 is associated with an acceptable safety profile and elicits durable remission rates in heavily pretreated patients who have relapsed/refractory lymphoma following prior CAR T-cell therapy.

In the field of lymphoma, there are several areas needing improvement, with a significant unmet need among patients who progress after receiving currently available anti-CD19 CAR T-cell therapies, Svoboda begins. These patients, particularly those who are relapsed/refractory following such treatments, were the focus of the clinical trial presentation at ASCO, he states. The innovative aspect of this product, referred to as an armored CAR T-cell therapy or fourth-generation CAR T-cell therapy, lies in its enhancements over existing therapies, Svoboda reports. This product is an autologous T-cell therapy similar to those currently on the market, but it includes modifications aimed at improving efficacy, he adds.

One key modification is that huCART19-IL18 can secrete interleukin (IL)–18, a pro-inflammatory cytokine, Svoboda expands. Preclinical studies indicate that IL-18 boosts the cytotoxic potential of T cells and may also alter the tumor microenvironment (TME), he says. Additionally, IL-18 exhibits anti-lymphoma properties. These enhancements, combined with the specificity of the CAR targeting CD19, provide significant advantages, Svoboda elucidates. By enhancing the cytolytic capabilities of T cells and potentially improving the TME, IL-18 contributes to the product’s overall efficacy against lymphoma, he notes. This phase 1, first-in-human clinical trial (NCT04684563) explored huCART19-IL18 to address unmet needs for patients relapsing after anti-CD19 CAR T-cell therapies, Svoboda concludes.

Related Videos
Joseph Franses, MD, PhD
Shipra Gandhi, MD
Chih-Yi Liao, MD
Mazyar Shadman, MD, MPH
Sheldon M. Feldman, MD
Rita Mukhtar, MD
Lajos Pusztai, MD, DPhil
Hope S. Rugo, MD
Marc Machaalani, MD
Craig Eckfeldt, MD, PhD, assistant professor, medicine, faculty, Microbiology, Immunology, and Cancer Biology PhD Graduate Program, Division of Hematology, Oncology, and Transplantation, the University of Minnesota Medical School